Title: Efficacy and Safety of Garenoxacin versus Moxifloxacin in Acute Exacerbation of COPD: A Comparative Study
Authors: Dr D C Punera, Dr Ajay Sinha, Dr Renu Khanchandani, Dr Bhavana Srivastava, Dr Reena Bhardwaj, Dr Siddharth Ahuja
DOI: http://dx.doi.org/10.18535/jmscr/v4i8.74
Aim: The aim of the present study was to compare the efficacy and safety of Garenoxacin with that of Moxifloxacin for the treatment of patients of Acute exacerbations of COPD. Material and Method: This study was a prospective, open label, observational, comparative study; where clinically diagnosed COPD patients of either sex in age group of 25-70 years with clinical symptoms suggestive of Acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) were enrolled. After obtaining written informed consent, Patients were divided into two treatment groups. Group A Moxifloxacin 400 mg once daily for 5 days while group B received Garenoxacin 400 mg once daily for 5 days. Primary outcome measure (cure, improved, failure), that is clinical success rate is assessed at day 14. Result: Mean age (± 2SD) of the COPD patients in Garenoxacin group was 60.98 ± 10.67 whereas in Moxifloxacin group the mean age (± 2SD) was 57.80 ± 10.27. In Garenoxacin group, 14 patients achieved cure and rest 36 patients achieved improved whereas in Moxifloxacin group, 8 patients achieved cure, 41 patient achieved improvement and 1 patient did not respond to treatment and was termed failure. Observed adverse event were few, mild and self limiting in both group. Conclusion: 5-day course of Garenoxacin is therapeutically comparable to Moxifloxacin in terms of clinical effectiveness in AECOPD. Keywords- Acute exacerbations of COPD, Garenoxacin, Moxifloxacin.
Abstract
